Surmodics Acquisition & Valuation

Surmodics was acquired by GTCR for $627M in May 2024, a 4.7x multiple on $133M of revenue.

Surmodics acquisition price

$627M

Acquired by GTCR · May 2024

Surmodics revenue at acquisition

$133M

Last twelve months · May 2024

Surmodics revenue multiple at acquisition

4.7x

EV/Revenue · May 2024

Surmodics Overview

About Surmodics

Surmodics is a provider of medical device coatings, including the largest U.S. supplier of hydrophilic coatings for catheters and guidewires, along with in vitro diagnostic technologies for the healthcare industry. Its device portfolio includes thrombectomy catheters such as the Pounce arterial thrombus retrieval system and the ReVene venous thrombectomy catheter, along with minimally invasive catheter technologies for complex interventional procedures. Surmodics serves medical device manufacturers and healthcare providers across catheter-based and vascular procedures.


HQ

United StatesUnited States

Status

Acquired

Customer focus

B2B

Revenue model

Product sales

Revenue

$133M (May 2024)

Valuation

$627M (acquired May 2024)

Surmodics Acquisition

Surmodics was acquired by GTCR for $627M on 29 May 2024.

The acquisition price implies a 4.7x revenue multiple on $133M of revenue.

Surmodics, Inc., a provider of medical device coatings, including the largest U.S. supplier of hydrophilic coatings for catheters and guidewires, and in vitro diagnostic technologies to the healthcare industry, entered into a definitive merger agreement on May 29, 2024, to be acquired by affiliates of GTCR, a private equity firm with extensive expertise in healthcare and healthcare technology. GTCR will acquire all outstanding shares for $43.00 per share in cash, valuing the equity at approximately $627 million, a 41.1% premium to Surmodics’ 30-trading day volume-weighted average closing price through May 28, 2024. The deal is financed through committed equity from GTCR funds and debt financing; upon closing, Surmodics will become privately held and delist from Nasdaq. Surmodics’ board unanimously approved the transaction and recommended shareholder approval, with CEO Gary Maharaj highlighting GTCR’s domain expertise as ideal for future growth in serving physicians, patients, and customers. Needham analysts noted the deal’s fair valuation and lack of major antitrust risks despite GTCR’s prior investment in Biocoat, another coatings developer, suggesting potential cost-saving synergies as their combined market shares remain low. The transaction faced FTC scrutiny over alleged 50-60% control in outsourced hydrophilic coatings, high HHI increases exceeding 1,000, and loss of head-to-head competition, prompting a July 29, 2025, divestiture to Integer of 10 Biocoat products, 11 employees, a production facility, and partial customer contracts. A U.S. District Court in Illinois denied the FTC’s November 2025 preliminary injunction motion on November 10, 2025, citing the divestiture’s effectiveness, business testimony, and a strong defense expert; regulators chose not to appeal. As of November 17, 2025, Surmodics expected prompt closing subject to customary conditions including no material adverse effects, shareholder approval, and absence of legal restraints, originally targeted for H2 2024 but delayed by regulatory review.

Surmodics acquisition details
AcquirerDateTypePriceEV/Revenue
  • GTCR
29 May 2024PE buyout$627M4.7x

Sources: sec.gov, sec.gov

Acquisitions by Surmodics

Surmodics has acquired 5 companies to date.

Last acquisition by Surmodics was on October 1st 2026. Surmodics acquired Alta Biomed for undisclosed valuation.


Latest Acquisitions by Surmodics

Alta Biomed
Biocoat
Vetex Medical
NorMedix
Description
Alta Biomed is a medical device materials company that develops, manufactures and sells antithrombotic, pro-endothelializing coatings for blood-contacting devices. Its technology portfolio is built around Polyzene-F (PzF), alongside related coating products such as COBRA PzF, NCS and Xero-Gel. The company also offers testing services, including hemocompatibility evaluation under ISO 10993-4 blood loop testing, thrombosis evaluation, acute particulate testing, coating thickness measurement and surface characterization. Its coating work covers materials such as ePTFE and catheter components. Customers are medical device makers, and revenue comes from coating products and fee-based testing and coating services. Alta Biomed is based in Indianapolis, Indiana, and was founded in 2023.
Biocoat is a Horsham, Pennsylvania-based specialist in hydrophilic coatings for catheters, guidewires, and stents. Its Hydrolene portfolio includes permanent and RMCR lubricious layers with coefficients below 0.02, applied via solventless processes for diameters from 0.5 French. Founded in 1991, the company coats devices for Abbott, Medtronic, and Boston Scientific, with ISO 13485 facilities producing 10 million feet of coated product yearly.
Vetex Medical is a Galway-based medical device firm developing thrombectomy catheters for venous thromboembolism treatment. The company's platform technology targets deep vein thrombosis in ilio-femoral veins, AV fistula grafts, and pulmonary embolism, enabling single-session thrombus removal. Incorporated in 2013, Vetex Medical has secured CE Mark approval for its device and initiated U.S. FDA pivotal trials in 2022. Its catheters feature helical basket designs for efficient clot retrieval, addressing a market projected to exceed $1 billion by 2025, with clinical data from over 50 procedures demonstrating 90% success rates.
NorMedix was a design and development firm in Plymouth, Minnesota, focused on ultra thin-walled, minimally invasive catheter technologies. It was acquired by SurModics in 2016.
HQ CountryUnited StatesUnited StatesIrelandUnited States
HQ City
Indianapolis, IN
Philadelphia, PA
Galway
Plymouth
Deal Date1 Oct 202610 Dec 20256 Jul 202111 Jan 2016
Valuationundisclosedundisclosed$40M$14M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Surmodics acquisitions and their M&A valuation multiples.

Start Free Trial

Surmodics Competitors

Surmodics competitors include listed companies like Cerus, Xvivo Perfusion, Sunmax Biotechnology and Nanosonics, and private ones like Galvanize Therapeutics and Delfi Diagnostics.

Public and private companies comparable to Surmodics
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
CerusUnited StatesUnited StatesPublicly listed$206M($5M)$408M1.7x
Xvivo PerfusionSwedenSwedenPublicly listed$83M$11M$634M6.2x
Sunmax BiotechnologyTaiwanTaiwanPublicly listed$62M$34M$646M-
NanosonicsAustraliaAustraliaPublicly listed$141M$17M$599M3.4x
Galvanize TherapeuticsUnited StatesSan Francisco, CAPrivate--$650M-
Delfi DiagnosticsUnited StatesBaltimore, MDPrivate--$685M-

Surmodics Public Comps

Surmodics is no longer listed, but its public comps include Xvivo Perfusion, Sunmax Biotechnology, Nanosonics, Medistim, Lumibird, Tactile Medical, SD Biosensor, Curiox Biosystems, Barco and Myriad Genetics.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Xvivo Perfusion$83M$11M7.4x6.2x57.8x30.4x
Sunmax Biotechnology$62M$34M10.2x-18.5x-
Nanosonics$141M$17M3.6x3.4x29.6x31.8x
Medistim$75M$25M7.8x6.8x23.4x21.3x
Lumibird$256M$47M2.7x2.5x14.4x12.1x
Tactile Medical$330M$36M1.6x1.5x14.6x10.5x
SD Biosensor$525M($517M)0.9x-(0.9x)-
Curiox Biosystems$4M($18M)150.0x-(32.5x)-

This data is available for Pro users. Sign up to see all Surmodics competitors and their valuation data.

Start Free Trial

Common questions about Surmodics

Where is Surmodics headquartered?Surmodics is headquartered in United States.
Is Surmodics publicly listed?No, Surmodics was acquired by GTCR in May 2024.
Who acquired Surmodics?Surmodics was acquired by GTCR in May 2024.
How much was Surmodics acquired for?Surmodics was acquired for $627M in May 2024, a 4.7x revenue multiple.
Which companies are comparable to Surmodics?Companies comparable to Surmodics include Cerus, Xvivo Perfusion, Sunmax Biotechnology, Nanosonics, Galvanize Therapeutics and Delfi Diagnostics.
How many companies has Surmodics acquired?Surmodics has acquired 5 companies, including Alta Biomed, Biocoat, Vetex Medical, NorMedix and Creagh Medical.
What was the largest acquisition by Surmodics?The $40M acquisition of Vetex Medical in July 2021 is the largest acquisition Surmodics has made to date.

See companies similar to Surmodics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial